- Open Access
Book Review:Prevention and Recovery from Eating Disorders in Type 1Diabetes:Injecting Hope
© The Author(s). 2019
- Received: 3 January 2019
- Accepted: 9 January 2019
- Published: 30 January 2019
“Good things come in tiny packages” exemplifies this 120-page volume written by Dr. Goebel-Fabbi . It reflects her many years of clinical practice and wisdom as well as being embedded in empirical research and science. The first chapter is a narrative review of Eating Disorders as they occur in people with Type 1 diabetes mellitus (T1DM) with an introductory overview of both problems, predisposing risks and vulnerabilities, course and broad recommendations for treatment. A model of the interplay between cognitions, emotions, behaviors (notably insulin restriction) and physical/psychological symptoms (e.g. edema, depression) is presented.
The major content of the book is a series of 10 chapters presenting a thematic analysis of interviews of 25 women with T1DM who have experienced recovery (albeit not always complete remission) from an eating disorder. Each chapter takes a phase of people’s journeys from prevention, through seeking treatment and barriers, treatment experience, and life after treatment, including a chapter for people who continue to have eating disorder symptoms. The chapters follow a similar format, starting with emergent themes, and ending with a list of clinical learning points and a case study. There is an abundance of useful practice advice for both the eating disorder clinician and the diabetes specialist. A case in point is that commencing insulin is in itself an eating disorder “risk factor” as there is usually weight gain. A validating acceptance of dialectics common in people with eating disorders is outlined. Thus, rather than admonishing poor adherence, the clinician is encouraged to appreciate that the person can hold an extreme fear of weight gain (and insulin treatment) whilst sincerely wishing to have well controlled blood sugar levels and an improved metabolic status.
The book is very relevant for all clinicians working in either area, eating disorders or T1DM. Goebel-Fabbri highlights the paucity of research into the best management of comorbid eating disorders and T1DM. However, it is difficult to argue a randomized controlled trial is needed to support integrated care from eating disorder informed endocrinologists and diabetes informed eating disorder therapists. Whilst a single clinician may not often encounter the co-morbidity, when they do the challenges and potential for splitting of care are high. This book provides an important bridge across the knowledge divide.
People with lived experience would also find much in the book to help them navigate through treatment and recovery, particularly the accounts of people who have made good progress in their recovery journeys. As the title implies, these offer hope for others that they have a good chance as well to recover.
If I have a criticism it is that the book could be broader in context. For example it could have included consideration of these problems in men and people of other genders, and more resources outside North America. It is available through major online sellers and there is an electronic version on Kindle. It is not hard to obtain, well-written and should be widely read.
Availability of data and materials
PH Single author did all the writing. The author read and approved the final manuscript.
Professor Hay receives/has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and New South Wales Institute of Psychiatry and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, Biomed Central and PlosMedicine and she has received research grants from the NHMRC and ARC. She is Deputy Chair of the National Eating Disorders Collaboration Steering Committee in Australia (2012-) and Member of the ICD-11 Working Group for Eating Disorders (2012-) and was Chair Clinical Practice Guidelines Project Working Group (Eating Disorders) of RANZCP (2012–2015). She has prepared a report under contract and conducted education for Psychiatrists funded by Shire Pharmaceuticals (2017–2018). All views in this paper are her own.
Ethics approval and consent to participate
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.